Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
10 July 2020Website:
http://www.nkartatx.comNext earnings report:
09 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 03 Jul 2024 19:16:04 GMTDividend
Analysts recommendations
Institutional Ownership
NKTX Latest News
For investors looking to maximize profits, marking the appropriate cheap stocks is essential. Here, the focus is on three exceptional businesses, each with solid arguments for being included in a sharp investment plan.
Patient screening underway in Ntrust-1, the first U.S.-based clinical trial of an engineered NK cell therapy for the treatment of lupus nephritis
Senior R&D leader brings extensive expertise in immunology, clinical development and translational science Senior R&D leader brings extensive expertise in immunology, clinical development and translational science
Nkarta Inc. is using natural killer cells engineered with CARs and membrane-bound IL-15 to target autoimmune diseases and oncology. The company's off-the-shelf availability and superior safety profile make it an attractive option for patients, providers, and payers. Nkarta is targeting large markets, such as lupus nephritis and non-Hodgkin lymphoma, with the potential to produce blockbuster therapies.
NKTX has experienced a more than 50% decline from its peak in March 2024. The company is working on developing NKX019, a CAR-NK cell therapy that shows promise in treating cancer and autoimmune disorders. Initial data on NKX019 in oncology has been released, with more data expected in the middle of the year. The company has also begun exploring the potential of NKX019 in treating autoimmune diseases in the first half of 2024.
SOUTH SAN FRANCISCO, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in two upcoming investor conferences:
In the stock markets, where giants often steal the investment spotlight, hidden gems await discovery. Beyond the limelight lay under-the-radar stocks for 300% growth, teeming with potential and ready to soar to heights unimaginable to many investors.
Nkarta, Inc. (NKTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation at two upcoming investor conferences:
Nkarta (NKTX) rallies 112% on FDA nod to begin the clinical development of its investigational candidate, NKX019, for the treatment of lupus nephritis.
What type of business is Nkarta?
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
What sector is Nkarta in?
Nkarta is in the Healthcare sector
What industry is Nkarta in?
Nkarta is in the Biotechnology industry
What country is Nkarta from?
Nkarta is headquartered in United States
When did Nkarta go public?
Nkarta initial public offering (IPO) was on 10 July 2020
What is Nkarta website?
https://www.nkartatx.com
Is Nkarta in the S&P 500?
No, Nkarta is not included in the S&P 500 index
Is Nkarta in the NASDAQ 100?
No, Nkarta is not included in the NASDAQ 100 index
Is Nkarta in the Dow Jones?
No, Nkarta is not included in the Dow Jones index
When does Nkarta report earnings?
The next expected earnings date for Nkarta is 09 August 2024